ResMed - Public Comps and Valuation Multiples

ResMed Overview

About ResMed

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Founded

1994

HQ

Employees

10.0K+

Website

resmed.com

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $5.0B

LTM EBITDA $1.8B

EV

$31.8B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

ResMed Financials

ResMed has a last 12-month revenue of $5.0B and a last 12-month EBITDA of $1.8B.

In the most recent fiscal year, ResMed achieved revenue of $4.7B and an EBITDA of $1.5B.

ResMed expects next 12-month revenue of XXX and NTM EBITDA of XXX

See ResMed valuation multiples based on analyst estimates

ResMed P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$4.2B	$4.7B	XXX	XXX	XXX
Gross Profit	$2.0B	$2.4B	XXX	XXX	XXX
Gross Margin	48%	50%	XXX	XXX	XXX
EBITDA	$1.3B	$1.5B	XXX	XXX	XXX
EBITDA Margin	32%	33%	XXX	XXX	XXX
Net Profit	$779M	$898M	XXX	XXX	XXX
Net Margin	18%	19%	XXX	XXX	XXX
Net Debt	$502M	$1.2B	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

ResMed Stock Performance

As of April 15, 2025, ResMed's stock price is $215.

ResMed has current market cap of $31.5B, and EV of $31.8B.

See ResMed trading valuation data

ResMed Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$31.8B	$31.5B	XXX	XXX	XXX	XXX	$9.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

ResMed Valuation Multiples

As of April 15, 2025, ResMed has market cap of $31.5B and EV of $31.8B.

ResMed's trades at 6.3x LTM EV/Revenue multiple, and 17.6x LTM EBITDA.

Analysts estimate ResMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for ResMed and 10K+ public comps

ResMed Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$31.8B	XXX	XXX	XXX
EV/Revenue	6.5x	XXX	XXX	XXX
EV/EBITDA	18.7x	XXX	XXX	XXX
P/E	26.4x	XXX	XXX	XXX
P/E/Growth	1.7x	XXX	XXX	XXX
EV/FCF	24.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ResMed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

ResMed Valuation Multiples

ResMed's NTM/LTM revenue growth is 8%

ResMed's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, ResMed's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate ResMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for ResMed and other 10K+ public comps

ResMed Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	11%	XXX	XXX	XXX	XXX
EBITDA Margin	35%	XXX	XXX	XXX	XXX
EBITDA Growth	13%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	43%	XXX	XXX	XXX	XXX
Revenue per Employee	$0.5M	XXX	XXX	XXX	XXX
Opex per Employee	$0.1M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	7%	XXX	XXX	XXX	XXX
Opex to Revenue	27%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry